Navigation Links
NYP/Columbia physician-scientists present at ASCO 44th annual meeting
Date:5/30/2008

NEW YORK (May 29, 2008) -- Physician-scientists from NewYork-Presbyterian Hospital/Columbia University Medical Center will present their latest research findings at the American Society of Clinical Oncology Annual Meeting in Chicago, May 30 to June 3. Among the most significant presentations are the following:

  • Response Impressive for OncoVEXGM-CSF for Patients With Unresectable Metastatic Melanoma

    Dr. Howard L. Kaufman Chief of surgical oncology at NewYork-Presbyterian Hospital/Columbia University Medical Center, and chief of the Division of Surgical Oncology and the Edwin C. and Anne K. Weiskopf Associate Professor of Medicine at Columbia University College of Physicians and Surgeons

    OncoVEXGM-CSF is a herpes simplex virus (a microscopic life form commonly known as the "cold-sore virus") that has been genetically changed to grow in and destroy cancer cells. The investigators showed treatment success in 32 percent of patients. Other patients have also had clinical benefit, including two patients where tumors first noted during therapy responded, two patients who responded after leaving the study, and other patients with local palliative benefit in otherwise difficult-to-treat tumors. Researchers note that the rate and durability of response is impressive compared to other treatment options available to patients with advanced melanoma, particularly in the second line/salvage therapy setting. A Phase 3 study is being planned.

  • Early Oncologic Outcomes of Robotic Prostatectomy

    Dr. Erik T. Goluboff Director of urology at NewYork-Presbyterian Hospital/Allen Pavilion, and professor of urology at Columbia University College of Physicians and Surgeons

    Little is known about the oncologic outcomes of robotic prostatectomy. By reviewing a database of consecutive patients operated on by a single surgeon, researchers found that like other forms of prostatectomy, robotic prostatectomy provides excellent cancer control outcomes for clinically localized prostate cancer at short-term follow-up, with disease-free survival rates at 21 months.

  • Pathological Outcomes Vary by Institution for Robotic Prostatectomy

    Dr. Erik T. Goluboff Director of urology at NewYork-Presbyterian Hospital/Allen Pavilion, and professor of urology at Columbia University College of Physicians and Surgeons

    The pathological report of a radical prostatectomy specimen has critical prognostic significance and may affect postoperative management. Given inconsistencies in specimen processing and analysis, the accuracy of pathological reports was thought to vary between institutions. To test this hypothesis, researchers analyzed outcomes of robotic prostatectomy (removal of prostate using a robotic surgical device, usually for prostate cancer) based on a single high-volume surgeon who operated at two local institutions using the same technique and the same robotic team, and compared the pathologic outcomes. Findings affirmed that the institution affects pathological outcomes, and may account for some of the differences in reported rates of surgical margins.

  • Predicting Long-Term Survival Conditional on Years Survived Following Nephrectomy -- The Longer a Patient Survives, the Better Their Odds

    Dr. James McKiernan Urologist at NewYork-Presbyterian Hospital/Columbia University Medical Center and associate professor of urology at Columbia University College of Physicians and Surgeons

    In counseling patients after nephrectomy (surgical removal of the kidney) for renal cell carcinoma, the current literature estimates a five-year survival probability based on clinical and pathologic parameters. However, patients are not given an updated survival probability as a function of time. Investigators examined changes in 5- and 10-year survival probabilities conditional on years survived post-surgery and evaluated the effect of metastasis and local recurrence (LR) on these probabilities. The study showed that survival estimates increase significantly as the number of years survived increases, and the probability relates to the development of local recurrence and metastasis. These findings may affect how patients are monitored in the years following surgery.

  • Obesity Linked to Marker for Poor Survival in Patients With Liver Cancer (Hepatocellular Carcinoma)

    Dr. Abby Siegel Director of hepatobiliary oncology at the NewYork-Presbyterian Hospital/Columbia University Medical Center, and assistant professor of medicine at Columbia University College of Physicians and Surgeons

    Obesity is a risk factor for worsened outcomes in several types of cancer, including primary liver cancer (hepatocellular carcinoma, or HCC). The researchers hypothesized that tumor specimens from obese patients would be more likely than those from non-obese patients to show microvascular invasion, a known predictor of poor survival. The study found a significant association between obesity and increased microvascular invasion. A larger prospective study is planned.

  • Gemtuzumab Ozogamicin Is Safe and Well Tolerated for Children With Acute Myelogenous Leukemia (AML) After Allogeneic Stem Cell Transplantation

    Dr. Mitchell S. Cairo Chief of blood and marrow transplantation at Morgan Stanley Children's Hospital of NewYork-Presbyterian, and professor of pediatrics, medicine and pathology at Columbia University College of Physicians and Surgeons

    The transmembrane receptor CD33 is expressed in as much as 90 percent of childhood acute myelogenous leukemia (AML). The investigators found that Gemtuzamab therapy during conditioning or after allogenic stem cell transplantation in children with AML is safe and may prevent malignant relapse. They note that therapy may help reduce the risk of mortality and relapse in following allogeneic stem cell transplant in children with high-risk AML or following reduced-intensity AlloSCT in standard-risk AML.

  • Kinesin Spindle Protein (KSP) for Hodgkin's Lymphoma

    Dr. Owen O'Connor Director of Lymphoid Development and Malignancy Program at NewYork-Presbyterian Hospital/Columbia University Medical Center, and associate professor of medicine at Columbia University College of Physicians and Surgeons

    A Phase 1 dose-escalation trial of Kinesin Spindle Protein (KSP), a drug that targets a unique aspect of cancer cell division, has been found to be well tolerated and active in select patients with Hodgkin's disease.


'/>"/>

Contact: Gloria Chin
glc9010@nyp.org
212-305-5587
New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College
Source:Eurekalert

Related medicine news :

1. NewYork-Presbyterian/Columbia physician-scientists present at ACCs 57th Annual Scientific Session
2. BWF awards $11.2 million to support physician-scientists
3. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
4. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
5. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
6. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
7. Omnicell to Present at Thomas Weisel Healthcare Conference 2007
8. AtriCure to Present at Roth Capital Partners 2007 New York Conference
9. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
10. MDS to Present at Thomas Weisel Partners Healthcare Conference
11. Hospira to Present at the Bear Stearns 20th Annual Healthcare Conference on September 11
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... ... ... As directed by its board of directors during its April 26 meeting, ... certified nurse practitioners (CNP) to practice to the full scope of their license without ... years and 3,600 hours. , In addition, HAP supports CNPs who are licensed in ...
(Date:5/2/2016)... LINCOLN, R.I. (PRWEB) , ... May 02, 2016 ... ... , an educational website to help consumers better understand life insurance throughout various ... helpful resources, including an easy-to-use life insurance needs calculator and content specific to ...
(Date:5/2/2016)... ... May 02, 2016 , ... Dr. Philip Shindler, ... with same day treatments. In the past, many necessary dental treatments could require multiple ... with multiple anesthetic shots and extra chair time. Not only could this be inconvenient, ...
(Date:5/2/2016)... ... 2016 , ... Further establishing itself as a leader in natural pet products ... Boxes were selected from over 1,000 entrants as a winner and recipient of the ... chews for dogs are a favorite product among pet-parents worldwide, as each whimsical knobby ...
(Date:5/2/2016)... ... May 02, 2016 , ... ... that many commonly used prescription medications, including anxiolytics, painkillers, antidepressants and cholesterol-lowering ... risks, Novus Medical Detox Center —a leading Florida-based drug treatment facility—advises ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)...  The blood testing market in China ... Information and The Freedonia Group in a recent report.  ... The healthcare research firm said that China ... stations and in improving testing at the provincial level.  ... Blood Testing Market in China , which ...
(Date:4/28/2016)... , April 28, 2016 Dr. ... and Ste phen ... ArisGlobal®, a leading provider of cloud-based software solutions for life ... Pharmacovigilance team to bring a wealth of insight to a growing ... pharmacovigilance knowledge. George Phillips joined ArisGlobal in ...
(Date:4/28/2016)... 28, 2016  ValGenesis, Inc., the market ... (VLMS) today announced that a prominent world ... of chronic kidney failure has selected ValGenesis ... corporate validation process. The global medical device ... to manage their validation processes electronically. Upon ...
Breaking Medicine Technology: